Download PDF
Horm Metab Res 2016; 48(02): 83-91
DOI: 10.1055/s-0035-1565181
Review
© Georg Thieme Verlag KG Stuttgart · New York

Cerebrovascular Complications of Diabetes: Alpha Glucosidase Inhibitor as Potential Therapy

S. S. Patel
1   Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
› Author Affiliations
Further Information

Publication History

received 18 August 2015

accepted 16 October 2015

Publication Date:
17 November 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Increased risk of cerebrovascular accident in diabetes cannot be fully explained by traditional risk factors. Epidemiological studies show that postprandial hyperglycemia is strongly associated with cerebrovascular events and cerebrovascular-associated mortality. Postprandial hyperglycemia contributes to vascular damage by several mechanisms such as endothelial dysfunction, arthrosclerosis, oxidative stress, inflammation, and hypercoagulability. Hyperglycemia has deleterious effects on the vascular endothelium and leads to the development of cerebrovascular disease. Thus, an important strategy to reduce cerebrovascular risk in patients with diabetes is to reduce postprandial hyperglycemia. Glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and α-glucosidase inhibitors predominantly reduce postprandial plasma glucose levels. Among all of these, α-glucosidase inhibitors reduces postprandial hyperglycemia by delaying carbohydrate absorption from the intestine and this mechanism provides glycemic control without exacerbating coexisting cerebrovascular risk factors. Good glycemic control is proven to reduce the risk of cardiovascular complications, but equivalent evidence for cerebrovascular risk reduction is lacking. This review examines the evidences that postprandial hyperglycemia plays a major role in vascular damage, along with the complex interplay between hyperglycemia and coexisting risk factors. Furthermore, the mechanism by which α-glucosidase inhibitors may prevent this vascular damage as well as risk of hypoglycemia with α-glucosidase inhibitors are examined. Thus, this review suggests that α-glucosidase inhibitors are useful in reducing the risk of cerebrovascular events in patients with diabetes.

Key words

α-glucosidase inhibitors - cerebrovascular accident - diabetes - hyperglycemia - vascular damage
 

  • References

  • 1 Zhang M, Chen P, Chen S, Sun Q, Zeng QC, Chen JY, Liu YX, Cao XH, Ren M, Wang JK. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci 2014; 18: 1567-1572
    PubMedGoogle Scholar
  • 2 Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener 2011; 6: 11
    CrossrefPubMedGoogle Scholar
  • 3 Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006; 37: 345-350
    CrossrefPubMedGoogle Scholar
  • 4 Shah B, Mathur P. Workshop Report on Stroke Surveillance in India. Division of Noncommunicable Diseases. Indian Council of Medical Research; New Delhi: 2006
    Google Scholar
  • 5 Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E. Group DAIS . Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007; 38: 1154-1160
    CrossrefPubMedGoogle Scholar
  • 6 Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller R, Ewing I, Moomaw CJ, Szaflarski JP, Gebel J, Shukla R, Broderick JP. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355-359
    CrossrefPubMedGoogle Scholar
  • 7 Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Vasc Dis Res 2010; 7: 119-130
    CrossrefPubMedGoogle Scholar
  • 8 Sturgeon JD, Folsom AR, Longstreth Jr WT, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007; 38: 2718-2725
    CrossrefPubMedGoogle Scholar
  • 9 Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999; 30: 736-743
    CrossrefPubMedGoogle Scholar
  • 10 McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004; 490: 13-24
    CrossrefPubMedGoogle Scholar
  • 11 Haidari M, Zhang W, Willerson JT, Dixon RA. Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-beta-dependent vascular endothelial cadherin tyrosine phosphorylation. Cardiovascul Diabetol 2014; 13: 112
    PubMedGoogle Scholar
  • 12 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
    CrossrefPubMedGoogle Scholar
  • 13 Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Investig 2003; 112: 1049-1057
    CrossrefPubMedGoogle Scholar
  • 14 Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2007; 27: 435-451
    CrossrefPubMedGoogle Scholar
  • 15 Vazzana N, Ranalli P, Cuccurullo C, Davi G. Diabetes mellitus and thrombosis. Thromb Res 2012; 129: 371-377
    CrossrefPubMedGoogle Scholar
  • 16 Fagot-Campagna A, Rolka DB, Beckles GL, Gregg EW, Narayan KM. Prevalence of lipid ablormalities, awareness, and treatment in US adults with diabetes (Abstract). Diabetes 2000; 49 (Suppl. 01) A78
    PubMedGoogle Scholar
  • 17 Festa A, D’Agostino Jr R, Mykkanen L, Tracy RP, Hales CN, Howard BV, Haffner SM. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 1688-1693
    CrossrefPubMedGoogle Scholar
  • 18 Chan AC. Vitamin E and atherosclerosis. J Nutr 1998; 128: 1593-1596
    PubMedGoogle Scholar
  • 19 Gomes MB, Piccirillo LJ, Nogueira VG, Matos HJ. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab 2003; 29: 405-411
    CrossrefPubMedGoogle Scholar
  • 20 Esposito K, Giugliano D, Nappo F, Marfella R. Campanian Postprandial Hyperglycemia Study G . Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219
    CrossrefPubMedGoogle Scholar
  • 21 Gonzalez-Clemente JM, Mauricio D, Richart C, Broch M, Caixas A, Megia A, Gimenez-Palop O, Simon I, Martinez-Riquelme A, Gimenez-Perez G, Vendrell J. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol 2005; 63: 525-529
    CrossrefPubMedGoogle Scholar
  • 22 Ritter LS, Orozco JA, Coull BM, McDonagh PF, Rosenblum WI. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. Stroke 2000; 31: 1153-1161
    CrossrefPubMedGoogle Scholar
  • 23 Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002; 160: 501-509
    CrossrefPubMedGoogle Scholar
  • 24 Bemeur C, Ste-Marie L, Desjardins P, Vachon L, Butterworth RF, Hazell AS, Montgomery J. Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat. Neurochem Int 2005; 46: 399-407
    CrossrefPubMedGoogle Scholar
  • 25 Lin B, Ginsberg MD, Busto R, Li L. Hyperglycemia triggers massive neutrophil deposition in brain following transient ischemia in rats. Neuroscience letters 2000; 278: 1-4
    CrossrefPubMedGoogle Scholar
  • 26 Ste-Marie L, Hazell AS, Bemeur C, Butterworth R, Montgomery J. Immunohistochemical detection of inducible nitric oxide synthase, nitrotyrosine and manganese superoxide dismutase following hyperglycemic focal cerebral ischemia. Brain Res 2001; 918: 10-19
    CrossrefPubMedGoogle Scholar
  • 27 Xie H, Ray PE, Short BL. NF-kappaB activation plays a role in superoxide-mediated cerebral endothelial dysfunction after hypoxia/reoxygenation. Stroke 2005; 36: 1047-1052
    CrossrefPubMedGoogle Scholar
  • 28 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
    CrossrefPubMedGoogle Scholar
  • 29 Carr ME. Diabetes mellitus: a hypercoagulable state. Journal of diabetes and its complications 2001; 15: 44-54
    CrossrefPubMedGoogle Scholar
  • 30 Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485
    CrossrefPubMedGoogle Scholar
  • 31 Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57
    PubMedGoogle Scholar
  • 32 Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146
    CrossrefPubMedGoogle Scholar
  • 33 Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344 (Pt 1) 109-116
    CrossrefPubMedGoogle Scholar
  • 34 Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301
    CrossrefPubMedGoogle Scholar
  • 35 Soriano FG, Virag L, Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. Journal of molecular medicine 2001; 79: 437-448
    CrossrefPubMedGoogle Scholar
  • 36 Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes – part I: pathways of vascular disease in diabetes. Vascular pharmacology 2011; 54: 68-74
    CrossrefPubMedGoogle Scholar
  • 37 Schafer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60
    CrossrefPubMedGoogle Scholar
  • 38 Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radical Biol Med 1998; 25: 434-456
    CrossrefPubMedGoogle Scholar
  • 39 Iadecola C, Xu X, Zhang F, El-Fakahany EE, Ross ME. Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J Cereb Blood Flow Metab 1995; 15: 52-59
    CrossrefPubMedGoogle Scholar
  • 40 Fujimura M, Morita-Fujimura Y, Kawase M, Copin JC, Calagui B, Epstein CJ, Chan PH. Manganese superoxide dismutase mediates the early release of mitochondrial cytochrome C and subsequent DNA fragmentation after permanent focal cerebral ischemia in mice. J Neurosci 1999; 19: 3414-3422
    PubMedGoogle Scholar
  • 41 Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635-636
    CrossrefPubMedGoogle Scholar
  • 42 Zhang Z, Apse K, Pang J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 2000; 275: 40042-40047
    CrossrefPubMedGoogle Scholar
  • 43 Brzezinska AK, Gebremedhin D, Chilian WM, Kalyanaraman B, Elliott SJ. Peroxynitrite reversibly inhibits Ca(2+)-activated K(+) channels in rat cerebral artery smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1883-H1890
    PubMedGoogle Scholar
  • 44 Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998; 30: 146-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581
    CrossrefPubMedGoogle Scholar
  • 46 Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004; 64: 225-228
    CrossrefPubMedGoogle Scholar
  • 47 Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J. Investigators PR . Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873
    CrossrefPubMedGoogle Scholar
  • 48 Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009; 40: 604-609
    CrossrefPubMedGoogle Scholar
  • 49 Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. Atherosclerosis 2008; 201: 425-433
    CrossrefPubMedGoogle Scholar
  • 50 Venna VR, Li J, Hammond MD, Mancini NS, McCullough LD. Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. Eur J Neurosci 2014; 39: 2129-2138
    CrossrefPubMedGoogle Scholar
  • 51 Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (Suppl) 789-830
    PubMedGoogle Scholar
  • 52 Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Group L-S . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47
    CrossrefPubMedGoogle Scholar
  • 53 Balfour JA, McTavish D. Acarbose: An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-1054
    Google Scholar
  • 54 Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999; 57: 19-29
    PubMedGoogle Scholar
  • 55 He K, Shi JC, Mao XM. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clinl Risk Manag 2014; 10: 505-511
    PubMedGoogle Scholar
  • 56 Weng J, Soegondo S, Schnell O, Sheu WHH, Grzeszczak W, Watada H, Yamamoto N, Kalra S. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes/Metab Res Rev 2015; 31: 155-167
    CrossrefPubMedGoogle Scholar
  • 57 Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs 2003; 63: 933-951
    CrossrefPubMedGoogle Scholar
  • 58 van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163
    CrossrefPubMedGoogle Scholar
  • 59 Derosa G, Maffioli P. Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice. Archiv Med Sci 2012; 8: 899
    PubMedGoogle Scholar
  • 60 Kaku K. Efficacy of voglibose in type 2 diabetes. Expert Opin Pharmacother 2014; 15: 1181-1190
    CrossrefPubMedGoogle Scholar
  • 61 Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009; 329: 669-676
    CrossrefPubMedGoogle Scholar
  • 62 Laube H. Acarbose: An Update of Its Therapeutic Use in Diabetes Treatment. Clin Drug Investig 2002; 22: 141-156
    CrossrefPubMedGoogle Scholar
  • 63 Philip E, Sundaram ML, Das R, Chauhan SK, Deshpande S, Ambhore S, Rathod R, Manjrekar P. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab 2013; 17: S674
    CrossrefPubMedGoogle Scholar
  • 64 Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-175
    CrossrefPubMedGoogle Scholar
  • 65 Haffner SM, Valdez R, Morales PA, Mitchell BD, Hazuda HP, Stern MP. Greater effect of glycemia on incidence of hypertension in women than in men. Diabetes Care 1992; 15: 1277-1284
    CrossrefPubMedGoogle Scholar
  • 66 Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Suganami T, Kuzuya H, Ogawa Y. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 2006; 55: 786-793
    CrossrefPubMedGoogle Scholar
  • 67 Lee SM. The effect of chronic alpha-glycosidase inhibition on diabetic nephropathy in the db/db mouse. Diabetes 1982; 31: 249-254
    CrossrefPubMedGoogle Scholar
  • 68 Chen JM, Chang CW, Lin YC, Horng JT, Sheu WH. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J Diabetes Res 2014; 2014: 812628
    PubMedGoogle Scholar
  • 69 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Group S-NTR . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494
    CrossrefPubMedGoogle Scholar
  • 70 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Group S-NTR . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
    CrossrefPubMedGoogle Scholar
  • 71 Bavenholm PN, Efendic S. Postprandial hyperglycaemia and vascular damage – the benefits of acarbose. Diabetes Vasc Disease Res 2006; 3: 72-79
    PubMedGoogle Scholar
  • 72 Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078
    CrossrefPubMedGoogle Scholar
  • 73 Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-842
    CrossrefPubMedGoogle Scholar
  • 74 Wascher TC, Schmoelzer I, Wiegratz A, Stuehlinger M, Mueller-Wieland D, Kotzka J, Enderle M. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Investig 2005; 35: 551-557
    CrossrefPubMedGoogle Scholar
  • 75 Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T, Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res commun 2006; 345: 688-693
    CrossrefPubMedGoogle Scholar
  • 76 Vallejo S, Angulo J, Peiro C, Cercas E, Sanchez-Ferrer A, Nevado J, Llergo JL, Rodriguez-Manas L, Sanchez-Ferrer CF. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 2000; 36: 255-262
    CrossrefPubMedGoogle Scholar
  • 77 Rosen P, Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. Horm Metab Res 2006; 38: 575-586
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Aydin A, Orhan H, Sayal A, Ozata M, Sahin G, Isimer A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem 2001; 34: 65-70
    CrossrefPubMedGoogle Scholar
  • 79 Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Investig 1994; 24 (Suppl. 03) 3-10
    CrossrefPubMedGoogle Scholar
  • 80 Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004; 61: 461-470
    CrossrefPubMedGoogle Scholar
  • 81 Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 1997; 34: 104-112
    CrossrefPubMedGoogle Scholar
  • 82 Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, Ertl G, Bauersachs J. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J 2005; 19: 591-593
    PubMedGoogle Scholar
  • 83 Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes care 2000; 23: 1162-1167
    CrossrefPubMedGoogle Scholar
  • 84 Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106: 231-233
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200
    PubMedGoogle Scholar
  • 86 Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, Fischer S. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract 2002; 55: 221-227
    CrossrefPubMedGoogle Scholar
  • 87 Rudofsky Jr G, Reismann P, Schiekofer S, Petrov D, von Eynatten M, Humpert PM, Isermann B, Muller-Hoff C, Thai TP, Lichtenstein S, Bartsch U, Hamann A, Nawroth P, Bierhaus A. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004; 36: 630-638
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Shinoda Y, Inoue I, Nakano T, Seo M, Sassa M, Goto S, Awata T, Komoda T, Katayama S. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism 2006; 55: 935-939
    CrossrefPubMedGoogle Scholar
  • 89 Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-473
    CrossrefPubMedGoogle Scholar
  • 90 Kado S, Murakami T, Aoki A, Nagase T, Katsura Y, Noritake M, Matsuoka T, Nagata N. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 49-55
    CrossrefPubMedGoogle Scholar
  • 91 Scott R, Lintott CJ, Zimmet P, Campbell L, Bowen K, Welborn T. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?. Diabetes Res Clin Pract 1999; 43: 179-185
    CrossrefPubMedGoogle Scholar
  • 92 Kawamura T, Egusa G, Fujikawa R, Watanabe T, Oda K, Kataoka S, Takayama S, Kubo K, Yamamoto S, Noma K, Orita R, Yamakido M. Effect of acarbose on glycemic control and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Curr Ther Res 59: 97-106
    PubMedGoogle Scholar
  • 93 Mughal MA, Memon MY, Zardari MK, Tanwani RK, Ali M. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pakistan Med Assoc 2000; 50: 152-156
    PubMedGoogle Scholar
  • 94 Yamasaki Y, Katakami N, Hayaishi-Okano R, Matsuhisa M, Kajimoto Y, Kosugi K, Hatano M, Hori M. alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 2005; 67: 204-210
    CrossrefPubMedGoogle Scholar
  • 95 Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381
    CrossrefPubMedGoogle Scholar
  • 96 Rosenbaum P, Peres RB, Zanella MT, Ferreira SR. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Brazilian J Med Biol Res 2002; 35: 877-884
    CrossrefPubMedGoogle Scholar
  • 97 Rosenthal J, Mauersberger H. Effects on Blood Pressure of the α-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus. Clin Drug Investig 2002; 22: 695-701
    CrossrefPubMedGoogle Scholar
  • 98 Shibao C, Gamboa A, Diedrich A, Dossett C, Choi L, Farley G, Biaggioni I. Acarbose an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension 2007; 50: 54-61
    CrossrefPubMedGoogle Scholar
  • 99 Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. In: The Cochrane Collaboration. (ed.). Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd.; 2005
    Google Scholar